SCHEMBL4516875

SCHEMBL4516875

O=C(COc1ccc(CC2CCN(C3C4CC5CC3CC(O)(C5)C4)C2=O)c(Cl)c1)NCc1ccco1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.47
POLB P06746 3/20 0.43
ALDH1A1 P00352 8/20 0.42
HPGD P15428 5/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PKM P14618 1/20 0.41
TSHR P16473 2/20 0.41
MAPK1 P28482 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 2/20 0.40
HTT P42858 2/20 0.40
CASP1 P29466 1/20 0.40
RAB9A P51151 1/20 0.40
HIF1A Q16665 2/20 0.39
EPAS1 Q99814 2/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4515193 0.89 HSD11B1 (0.51) HSD11B1ALDH1A1HPGDTSHRGAA
SCHEMBL4502708 0.89 HSD11B1 (0.59) HSD11B1ALDH1A1HPGDTSHRGAA
SCHEMBL4514300 0.89 HSD11B1 (0.52) HSD11B1ALDH1A1HPGDMAPTGAA
SCHEMBL5541273 0.88 HSD11B1 (0.49) HSD11B1ALDH1A1GAA
SCHEMBL4501264 0.87 HSD11B1 (0.50) HSD11B1POLBALDH1A1HPGDGAA
SCHEMBL4515610 0.87 HSD11B1 (0.52) HSD11B1ALDH1A1GAAHTTKMT2A
SCHEMBL4518942 0.86 HSD11B1 (0.50) HSD11B1POLBALDH1A1GAAKMT2A
SCHEMBL4513448 0.86 HSD11B1 (0.49) HSD11B1POLBALDH1A1HPGDMAPT
SCHEMBL4505990 0.86 HSD11B1 (0.47) HSD11B1ALDH1A1PKMGAARAB9A
SCHEMBL4505009 0.86 HSD11B1 (0.49) HSD11B1POLBALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885POLB 2628/4885ALDH1A1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.